Want to see QNCX full AI Analyst Report?
Top Page
Quince Therapeutics
(NASDAQ:QNCX)
Select Model
Select Model
Rating:52Neutral
Price Target:
$25.00
▲(39.98% Upside)
Action:Reiterated
Date:08/04/26
The score is primarily held back by weak financial performance (pre-revenue status, sizable losses, and sustained cash burn). Offsetting factors include supportive corporate events (Nasdaq compliance regained and sizable financing alongside the Orphai acquisition) and positive near-term technical momentum, though overbought indicators increase pullback risk. Valuation remains constrained by negative earnings and no indicated dividend yield.
Positive Factors
Pipeline expansion via Orphai acquisition
Acquiring Orphai adds a clinical-stage inhaled rapamycin program and orphan indications, materially improving the company’s product pipeline. Coupled with a sizable private placement, this extends the development runway toward planned Phase 2 readouts and reduces single-asset concentration risk.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flows indicate the company is consuming cash to fund trials and operations. Over months this exhausts assets, forces frequent capital raises, and pressures program timelines if financing terms tighten or market access deteriorates.
Read all positive and negative factors
Positive Factors
Negative Factors
Pipeline expansion via Orphai acquisition
Acquiring Orphai adds a clinical-stage inhaled rapamycin program and orphan indications, materially improving the company’s product pipeline. Coupled with a sizable private placement, this extends the development runway toward planned Phase 2 readouts and reduces single-asset concentration risk.
Read all positive factors
Quince Therapeutics (QNCX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$22.87M
Dividend YieldN/A
Average Volume (3M)29.96K
Price to Earnings (P/E)―
Beta (1Y)0.47
Revenue GrowthN/A
EPS Growth35.04%
CountryUS
Employees38
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-124.60
Shares Outstanding977,963
10 Day Avg. Volume39,771
30 Day Avg. Volume29,956
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-4.70
Price to Sales (P/S)0.00
P/FCF Ratio-4.02
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$85.25Price Target Upside377.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-10.2
Revenue Forecast (FY)N/A
Quince Therapeutics Business Overview & Revenue Model
Company Description
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineer...
How the Company Makes Money
As a clinical-stage biotechnology company, Quince Therapeutics does not have a stable, recurring product-revenue base from commercial drug sales (null for material marketed-product revenue streams). Its funding and cash inflows have historically b...
Quince Therapeutics Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
38
Negative
Cash Flow
17
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -71.00K | -142.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -12.86M | -80.62M | -35.98M | -26.82M | -50.99M | -89.60M |
| Net Income | -33.04M | -83.98M | -56.83M | -31.39M | -51.66M | -89.94M |
Balance Sheet | ||||||
| Total Assets | 26.62M | 93.52M | 114.48M | 180.20M | 103.91M | 133.23M |
| Cash, Cash Equivalents and Short-Term Investments | 18.16M | 17.75M | 40.78M | 75.06M | 90.18M | 106.80M |
| Total Debt | 406.00K | 18.47M | 14.81M | 13.81M | 453.00K | 1.16M |
| Total Liabilities | 10.95M | 129.24M | 84.33M | 95.12M | 3.32M | 14.64M |
| Stockholders Equity | 15.67M | -35.71M | 30.15M | 85.08M | 100.59M | 118.59M |
Cash Flow | ||||||
| Free Cash Flow | -39.66M | -41.78M | -32.16M | -18.45M | -44.17M | -63.11M |
| Operating Cash Flow | -39.45M | -41.42M | -31.90M | -18.29M | -44.04M | -62.93M |
| Investing Cash Flow | 24.33M | 23.23M | 21.91M | -5.76M | 18.00M | 58.95M |
| Financing Cash Flow | 27.27M | 17.91M | -4.78M | 143.00K | 707.00K | 6.81M |
Quince Therapeutics Technical Analysis
Neutral
17.86
Price Trends
19.72
Positive
21.61
Positive
211.34
Negative
Market Momentum
1.42
Negative
80.84
Negative
88.28
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QNCX, the sentiment is Neutral. The current price of 17.86 is below the 20-day moving average (MA) of 19.76, below the 50-day MA of 19.72, and below the 200-day MA of 211.34, indicating a neutral trend. The MACD of 1.42 indicates Negative momentum. The RSI at 80.84 is Negative, neither overbought nor oversold. The STOCH value of 88.28 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for QNCX.
Quince Therapeutics Risk Analysis
Quince Therapeutics disclosed 42 risk factors in its most recent earnings report. Quince Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Quince Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $22.87M | -0.19 | 1823.49% | ― | ― | 35.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $177.70M | -7.95 | -48.20% | ― | 7336.90% | 49.64% | |
45 Neutral | $149.53M | -1.56 | -30.90% | ― | ― | 10.70% | |
44 Neutral | $64.40M | -0.57 | -59.06% | ― | ― | 49.00% | |
42 Neutral | $13.46M | -1.70 | -74.58% | ― | ― | 33.15% |
* Healthcare Sector Average
QNCX
Quince Therapeutics
27.41
-304.59
-91.74%
PLRX
Pliant Therapeutics
1.05
-0.64
-37.87%
NKTX
Nkarta
2.26
0.17
8.13%
ADAG
Adagene
3.64
1.27
53.59%
ANEB
Anebulo Pharmaceuticals
0.32
-2.38
-88.15%
Quince Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and FinancingShareholder Meetings
Quince Therapeutics Announces Leadership Transition to Orphai Team
Neutral
Jul 31, 2026
On July 29, 2026, Quince Therapeutics announced that CEO and Chief Medical Officer Dirk Thye, who also serves on the board, and COO, Chief Business Officer and Chief Compliance Officer Brendan Hannah tendered conditional resignations, effective tw...
Regulatory Filings and ComplianceShareholder MeetingsStock Split
Quince Therapeutics Implements 1-for-20 Reverse Stock Split
Neutral
Jun 26, 2026
On June 11, 2026, stockholders of Quince Therapeutics approved a reverse stock split at a ratio range of 1-for-10 to 1-for-100, and the board later set the ratio at 1-for-20. The company filed a certificate of amendment in Delaware on June 26, 202...
Executive/Board ChangesShareholder MeetingsStock Split
Quince Therapeutics Stockholders Approve Reverse Split Authorization
Neutral
Jun 11, 2026
On June 11, 2026, Quince Therapeutics held its annual meeting of stockholders via live webcast, with approximately 38.37% of outstanding shares represented. Stockholders elected June Bray as a Class I director to serve until the 2029 annual meetin...
Delistings and Listing ChangesRegulatory Filings and Compliance
Quince Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk
Positive
May 21, 2026
On March 17, 2026, Quince Therapeutics, Inc. was notified by the Nasdaq Listing Qualifications Department that it had failed to maintain the required minimum market value of listed securities of $50 million over 30 consecutive business days, putti...
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and Financing
Quince Therapeutics Closes Orphai Deal and Secures Funding
Positive
May 18, 2026
On May 18, 2026, Quince Therapeutics completed the stock-for-stock acquisition of clinical-stage Orphai Therapeutics, adding the LAM-001 inhaled rapamycin program and related orphan drug-designated indications to its portfolio, while also appointi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.